Cargando…
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and sa...
Autores principales: | Wong, Jeffrey Sum-Lung, Dong, Yawen, Tang, Vikki, Leung, Thomas, Yeung, Cynthia S. Y., Tai, Anna, Law, Ada, Shum, Tracy, Kwok, Gerry Gin-Wai, Li, Bryan Cho-Wing, Leung, Roland, Chiu, Joanne, Ma, Ka-Wing, She, Wong-Hoi, Tsang, Josephine, Cheung, Tan-To, Yau, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/ https://www.ncbi.nlm.nih.gov/pubmed/33919277 http://dx.doi.org/10.3390/cancers13092002 |
Ejemplares similares
-
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021) -
Hong Kong Registry Report 2004
por: Ho, Yiu-Wing, et al.
Publicado: (2005) -
A survey of the health and safety conditions of apartment buildings in Hong Kong
por: Ho, Daniel Chi-Wing, et al.
Publicado: (2008) -
Cyclospora infection in a young woman with human immunodeficiency virus in Hong Kong: a case report
por: Tsang, Owen Tak-yin, et al.
Publicado: (2013) -
A Digital Game and School-Based Intervention for Students in Hong Kong: Quasi-Experimental Design
por: Shum, Angie KY, et al.
Publicado: (2019)